Read through ONCOBIX's data.
4th-Generation Oral Medication for EGFR-Positive NSCLC
OBX02-011 is a candidate currently in the research and development stage to overcome various resistance mechanisms against the 3rd-generation NSCLC drugs. Notably, it is a multi-target NSCLC treatment with an excellent inhibitory effect against various mutations by inhibiting cancer-causing signaling systems effectively including EGFR, C797S double mutations, and C797S triple mutations.
Mechanism of Action
Drag left and right